Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Here’s What Happened
by Sarita Garza · The Markets DailyBavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw strong trading volume on Thursday. 5,993 shares changed hands during mid-day trading, an increase of 81% from the previous session’s volume of 3,305 shares. The stock last traded at $11.45 and had previously closed at $11.09.
Bavarian Nordic Stock Up 4.1%
The business’s 50-day moving average price is $10.43 and its 200 day moving average price is $9.92. The company has a market capitalization of $2.74 billion, a P/E ratio of 11.66 and a beta of 1.25.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The business had revenue of $316.47 million for the quarter.
Bavarian Nordic Company Profile
Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.
Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.